InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,705.45
(
-1.86%
)
US TECH 100
19,444.40
(
0.47%
)
Dow Jones
41,763.46
(
-0.90%
)
Brent Oil
74.66
(
0.87%
)
Bitcoin
69,397.92
(
-1.15%
)
Post# of 253503
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120650
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 99789

Wednesday, 07/28/2010 3:38:12 PM

Wednesday, July 28, 2010 3:38:12 PM

Post# of 253503
I’m not aware of a creatinine problem with IDX184. Among the places I looked was the poster presentation on IDX184 pharmacokinetics at EASL 2009:

http://www.idenix.com/hepc/drug/IDX184_Poster_(handout)_FInal_EASL09.pdf

My guess is that the analyst who asked about creatinine on the 2Q10 CC (Brian Abrahams of Oppenheimer) was merely being thorough, knowing that creatinine was a potential problem area insofar as IDX184 is excreted renally.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up